Holen Sie sich die Stockscreener-App
34.38
3.02%
-1.07
Schlusskurs vom Vortag:
$35.45
Offen:
$35.835
24-Stunden-Volumen:
11.81M
Relative Volume:
0.50
Marktkapitalisierung:
$7.96B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
65.85
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
-6.58%
1M Leistung:
+23.76%
6M Leistung:
+8.49%
1J Leistung:
-31.61%
1-Tages-Spanne:
$33.18
$36.46
1-Wochen-Bereich:
$33.18
$39.05
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
34.38 | 8.21B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.56 | 53.04B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.76 | 42.76B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.54B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.56 | 31.48B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.06 | 23.45B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
A Look at Hims & Hers Health Inc (HIMS) After 3.0% Decline -- GF Value $39.29 vs Price $34.38 - GuruFocus
Why Hims & Hers Health Shares Are Falling Today - Quiver Quantitative
Hims & Hers Health Stock (HIMS) Opinions on Recent Technical Breakouts and Growth Prospects - Quiver Quantitative
HIMS Stock Under Pressure: BofA Warns Wegovy Churn Could Threaten Its Big H2 EBITDA Ramp - Stocktwits
Hims & Hers Health (HIMS) Draws GLP 1 Attention, Is The Valuation Already Too Rich? - simplywall.st
HIMS Stock Rises Overnight: CEO Shrugs Off Wild Swings, Bets On ‘Gold Standard’ Of Healthcare Over Next Decade - Stocktwits
$Hims & Hers Health (HIMS.US)$ Why Wall Street is watching $HIMS beyond this quarter’s earnings - Moomoo
Truist reiterates Hold on Hims and Hers stock, $23 target on peptide uncertainty - Investing.com
Hims & Hers (HIMS) Stock Jumps 45% — Can This Momentum Continue? - Blockonomi
HIMS Maintains by B of A Securities -- Price Target Raised to $3 - GuruFocus
$Hims & Hers Health (HIMS.US)$ - Moomoo
BofA raises Hims and Hers stock price target to $37 on growth - Investing.com Canada
Hims & Hers Health (Ondo Tokenized Stock) Price - Decrypt
Hims & Hers Health: The Market Still Doesn't Get It - Seeking Alpha
Investor relations - HIMS Investor Relations
Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners - AOL.com
I Lost 35 Pounds of Postpartum Weight—Here’s How Hers Helped Me Do It - The Healthy @Reader's Digest
Technical Reactions to HIMS Trends in Macro Strategies - Stock Traders Daily
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market - Yahoo Finance
Hims & Hers CFO Okupe sells $261k in stock - Investing.com
Form 4 Hims Hers Health Inc For: 7 July By Investing.com - Investing.com Nigeria
Hims & Hers CFO Okupe sells $261k in stock By Investing.com - Investing.com Canada
Hims & Hers (NYSE: HIMS) CFO exercises options and sells 7,163 shares under 10b5-1 plan - Stock Titan
Hims & Hers Pullback Could Create a Better Entry Into GLP-1 Demand - Investing.com
HIMS Stock Slips Overnight After FDA Staff Questions Safety Of Popular Peptides — But One Analyst Says ‘This Isn’t The End’ - Stocktwits
HIMS Stock Hits 2026 High After Unlocking $400M Working Capital Through JPMorgan — Retail Gets Less Bearish - Stocktwits
Hims & Hers (HIMS) Stock May Be Undervalued After FDA Peptide Questions - Yahoo Finance
Hims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Hims & Hers Health Inc (HIMS) Stock Up 4.0% and Still Undervalued -- GF Score: 81/100 - GuruFocus
Form 144 Hims & Hers Health For: 6 July By Investing.com - Investing.com Canada
[144] Hims & Hers Health, Inc. SEC Filing - Stock Titan
Hims & Hers Health Options Spot-On: On July 6th, 112.7K Contracts Were Traded, With 1.01 Million Open Interest - Moomoo
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner - MarketBeat
Hims & Hers Health Options Spot-On: On July 2nd, 125.75K Contracts Were Traded, With 987.85K Open Interest - Moomoo
Hims & Hers Health stock falls as insider files to sell shares - Investing.com
HIMS Breakout Signals Structural Business Transformation (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health Inc at Morgan Stanley Technology, Media & Telecom Conference Transcript - GuruFocus
Hims & Hers Health Inc Stock Baskets | XSWX:HIMS - GuruFocus
Hims & Hers Health Inc (XSWX:HIMS) Stock News, Headlines & Updates - GuruFocus
Hims & Hers Health Inc (XSWX:HIMS) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Hims & Hers Health Inc (XSWX:HIMS) Stock Price & 30 Year Financial Data - GuruFocus
Hims & Hers Health Inc Stock Operating Data - GuruFocus
Hims & Hers Health Inc (XSWX:HIMS) Stock Earnings Transcripts - GuruFocus
HIMS News | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
Hims & Hers Health (HIMS) 2026 Evercore Global TMT Conference Summary - Quartr
Hims & Hers Health, Inc.: Target Price Consensus and Analysts Recommendations | HIMS | US4330001060 - marketscreener.com
HIMS Stock Jumps 8% as JPMorgan Facility and Analyst Upgrades Fuel Rally - FXLeaders
Hims & Hers Health Enters Receivables Purchase Agreement with JPMorgan Chase Bank – Key Terms and Details - Minichart
Hims & Hers Establishes New $400 Million Receivables Facility - TipRanks
Hims & Hers Launches $400 Million Receivables Facility, Amends Revolver to Support Program - TradingView
Hims & Hers (HIMS) adds $400M receivables facility and amends credit deal - Stock Titan
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.42%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):